PMID- 10489871
OWN - NLM
STAT- MEDLINE
DCOM- 19991025
LR  - 20190915
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 22
IP  - 4
DP  - 1999 Aug
TI  - Protective antitumor activity through dendritic cell immunization is mediated by 
      NK cell as well as CTL activation.
PG  - 340-7
AB  - Dendritic cells (DCs) are potent professional antigen-presenting cells (APC) 
      capable of inducing the primary T cell response to antigen. Although tumor cells 
      express target antigens, they are incapable of stimulating a tumor-specific 
      immune response due to a defect in the costimulatory signal that is required for 
      optimal activation of T cells. In this work, we describe a new approach using 
      tumor-DC coculture to improve the antigen presenting capacity of tumor cells, 
      which does not require a source of tumor-associated antigen. Immunization of a 
      weakly immunogenic and progressive tumor cocultured with bone marrow-derived DCs 
      generated an effective tumor vaccine. Immunization with the cocultured DCs was 
      able to induce complete protective immunity against tumor challenges and was 
      effective for the induction of tumor-specific CTL (cytotoxic T lymphocyte) 
      activity. Furthermore, high NK cell activity was observed in mice in which tumors 
      were rejected. In addition, immunization with tumor-pulsed DCs induced delayed 
      tumor growth, but not tumor eradication in tumor-bearing mice. Our results 
      demonstrate that coculture of DCs with tumors generated antitumor immunity due to 
      the NK cell activation as well as tumor-specific T cell. This approach would be 
      useful for designing tumor vaccines using DCs when the information about tumor 
      antigens is limited.
FAU - Kim, K D
AU  - Kim KD
AD  - Korea Research Institute of Bioscience and Biotechnology, Taejon.
FAU - Kim, J K
AU  - Kim JK
FAU - Kim, S J
AU  - Kim SJ
FAU - Choe, I S
AU  - Choe IS
FAU - Chung, T H
AU  - Chung TH
FAU - Choe, Y K
AU  - Choe YK
FAU - Lim, J S
AU  - Lim JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Indicators and Reagents)
SB  - IM
MH  - Animals
MH  - Antibodies, Neoplasm/*immunology
MH  - Antigens, Neoplasm/immunology
MH  - Bone Marrow Cells/immunology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Cytotoxicity Tests, Immunologic
MH  - Dendrites/*immunology
MH  - Flow Cytometry
MH  - Indicators and Reagents
MH  - Killer Cells, Natural/*immunology
MH  - Lymphocyte Activation/*immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Phenotype
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1999/09/18 00:00
MHDA- 1999/09/18 00:01
CRDT- 1999/09/18 00:00
PHST- 1999/09/18 00:00 [pubmed]
PHST- 1999/09/18 00:01 [medline]
PHST- 1999/09/18 00:00 [entrez]
AID - 10.1007/BF02979055 [doi]
PST - ppublish
SO  - Arch Pharm Res. 1999 Aug;22(4):340-7. doi: 10.1007/BF02979055.